B7-H3 (CD276): Biology, Clinical Significance, and Emerging Therapeutic Opportunities in Cancer Immunotherapy

B7-H3 (CD276) is an emerging immune checkpoint molecule with significant relevance in cancer biology and immunotherapy. Although initially described as a costimulatory signal, accumulating evidence indicates that B7-H3 primarily functions as an immune inhibitory regulator within the tumor microenvironment. Its low expression in normal tissues and high, homogeneous overexpression in a wide range of solid tumors make it an attractive biomarker and therapeutic target. Beyond immune modulation, B7-H3 promotes tumor progression, angiogenesis, and treatment resistance. These features have driven the rapid development of B7-H3–targeted therapies, particularly antibody–drug conjugates and cell-based immunotherapies.

What Is B7-H3 (CD276)?

B7-H3, also known as CD276, is a member of the B7 family of immune regulatory molecules, a group best known for its role in immune checkpoint signaling. The B7 family includes well-established targets such as PD-L1 (B7-H1) and CTLA-4 ligands, and B7-H3 has emerged as an important next-generation molecule within this class. Structurally, B7-H3 is a type I transmembrane glycoprotein encoded by the CD276 gene and is typically expressed as a 2Ig or 4Ig domain isoform in humans.

B7-H3 was initially identified in the early 2000s as a potential costimulatory molecule that could enhance T-cell activation. However, subsequent studies have revealed a more complex and, in many contexts, opposing role. In cancer and chronic inflammatory settings, B7-H3 is now more commonly associated with immune inhibition, contributing to tumor immune evasion. Unlike classical immune checkpoints, the counter-receptor for B7-H3 has not been definitively identified, making it a unique and somewhat enigmatic target in immunology.

One of the most distinctive features of B7-H3 is its expression pattern. In normal tissues, B7-H3 expression is generally low and tightly regulated. In contrast, it is highly overexpressed across a wide range of solid tumors, including lung, prostate, breast, ovarian, and pediatric cancers such as neuroblastoma. This tumor-selective expression has driven significant interest in B7-H3 as both a biomarker and a therapeutic target.

Beyond immune regulation, accumulating evidence suggests that B7-H3 also plays non-immunological roles in cancer biology, influencing tumor cell proliferation, migration, angiogenesis, and resistance to therapy. These combined immune and tumor-intrinsic functions position B7-H3 as a critical molecule at the intersection of cancer progression and immune escape, and explain why it has become a focal point for modern oncology drug development.

Biological Function and Mechanism of Action of B7-H3

The biological function of B7-H3 (CD276) remains one of the most debated topics in immune checkpoint biology. Early studies described B7-H3 as a costimulatory molecule capable of enhancing T-cell activation, proliferation, and interferon-γ (IFN-γ) production. However, as research expanded into tumor immunology and chronic disease models, accumulating evidence has shifted consensus toward B7-H3 functioning predominantly as an immune inhibitory regulator, particularly within the tumor microenvironment.

One of the defining features—and challenges—of B7-H3 biology is that its counter-receptor has not been conclusively identified. Unlike PD-1/PD-L1 or CTLA-4/CD80-CD86 pathways, the absence of a clearly defined receptor complicates mechanistic interpretation. Despite this, functional studies consistently demonstrate that B7-H3 expression on tumor cells, stromal cells, and tumor-associated vasculature is associated with suppressed T-cell activation, reduced cytokine secretion, and impaired antitumor immune responses.

In the tumor microenvironment, B7-H3 contributes to immune evasion by inhibiting CD8⁺ cytotoxic T lymphocytes and potentially modulating NK cell activity. Its expression often correlates with an immunosuppressive milieu characterized by low T-cell infiltration and resistance to immune checkpoint blockade therapies targeting PD-1 or PD-L1. This suggests that B7-H3 operates through non-redundant immune pathways, reinforcing its appeal as a complementary or alternative immunotherapy target.

Beyond immune modulation, B7-H3 also exerts tumor-intrinsic effects. Multiple studies indicate that B7-H3 signaling promotes cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT). Mechanistically, these effects have been linked to pathways such as PI3K/AKT, JAK/STAT, and NF-κB, although the precise signaling cascades remain context dependent. Additionally, B7-H3 expression has been associated with angiogenesis and resistance to chemotherapy and radiotherapy.

Collectively, the dual role of B7-H3—combining immune suppression with direct tumor-promoting functions—distinguishes it from classical immune checkpoints and underscores its importance in cancer progression and therapeutic targeting.

B7-H3 Expression in Cancer and Clinical Significance

A defining characteristic of B7-H3 (CD276) is its distinctive expression profile in malignant versus normal tissues, which underpins its growing clinical importance in oncology. While B7-H3 mRNA can be detected in a variety of normal tissues, protein expression on the cell surface is typically low or absent under physiological conditions. In contrast, marked overexpression of B7-H3 protein has been consistently observed across a wide range of solid tumors, making it a highly attractive tumor-associated antigen.

High B7-H3 expression has been documented in cancers such as non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, colorectal cancer, head and neck squamous cell carcinoma, and neuroblastoma. Notably, B7-H3 is expressed not only on tumor cells themselves but also on tumor-associated vasculature and stromal components, further broadening its relevance within the tumor microenvironment. This multi-compartment expression pattern enhances its accessibility for antibody-based therapeutic strategies.

Clinically, elevated B7-H3 expression is frequently associated with poor prognosis. Numerous retrospective studies have linked high B7-H3 levels to advanced tumor stage, increased metastatic potential, higher recurrence rates, and reduced overall survival. In prostate and lung cancers, for example, B7-H3 expression correlates with aggressive disease phenotypes and resistance to standard therapies. In pediatric tumors such as neuroblastoma, B7-H3 is expressed at particularly high and homogeneous levels, supporting its role as both a prognostic marker and a therapeutic target.

Importantly, B7-H3 expression often correlates with an immunologically “cold” tumor microenvironment, characterized by low T-cell infiltration and diminished response to PD-1/PD-L1 blockade. This suggests that B7-H3 may contribute to primary or acquired resistance to current immunotherapies. As a result, B7-H3 is increasingly viewed not only as a passive biomarker but as an active driver of immune escape and tumor progression.

Taken together, the tumor-selective overexpression of B7-H3 and its strong association with adverse clinical outcomes position it as a high-value biomarker and a compelling target for next-generation cancer therapies.

B7-H3 as a Therapeutic Target

The unique biological and clinical features of B7-H3 (CD276) have positioned it as one of the most promising next-generation targets in cancer therapy, particularly for solid tumors. Its high and relatively homogeneous expression in malignant tissues, combined with limited expression in normal organs, provides a strong therapeutic window for targeted interventions. In addition, B7-H3 is efficiently internalized upon antibody binding, a property that is especially advantageous for antibody-based drug delivery platforms.

Unlike classical immune checkpoints such as PD-1 or PD-L1, B7-H3 appears to regulate non-redundant immune suppressive pathways. This makes it an attractive option for patients who do not respond to existing immune checkpoint inhibitors. As a result, multiple therapeutic modalities targeting B7-H3 are currently under active clinical and preclinical development.

Among these, antibody–drug conjugates (ADCs) have emerged as the most advanced strategy. B7-H3–directed ADCs leverage tumor-selective antigen expression to deliver potent cytotoxic payloads directly to cancer cells, minimizing systemic toxicity. Early clinical data suggest encouraging antitumor activity across several solid tumor types, reinforcing the rationale for this approach.

Beyond ADCs, monoclonal antibodies targeting B7-H3 have been designed to block its immunosuppressive function and enhance antitumor immune responses. Bispecific antibodies are also being explored to simultaneously engage immune effector cells, such as T cells or NK cells, while targeting B7-H3–expressing tumors. In parallel, cell-based therapies, including CAR-T and CAR-NK cells, have demonstrated strong preclinical efficacy, particularly in pediatric solid tumors like neuroblastoma.

Another innovative strategy involves radiolabeled anti–B7-H3 antibodies, which combine targeted radiation delivery with antigen specificity. This approach has shown promise in tumors that are resistant to conventional therapies.

Collectively, these diverse therapeutic modalities highlight the versatility of B7-H3 as a target and underscore its potential to address unmet needs in solid tumor oncology. As clinical data continue to mature, B7-H3–directed therapies may become an integral component of future combination immunotherapy regimens.

Conclusion

B7-H3 (CD276) has rapidly emerged as a compelling target in modern cancer immunology, driven by its distinctive biology and strong clinical relevance. Its high and consistent expression across multiple solid tumors, coupled with limited presence in normal tissues, provides an attractive therapeutic window. Beyond its role in immune suppression, B7-H3 actively contributes to tumor growth, metastasis, and treatment resistance, setting it apart from classical immune checkpoints. The expanding pipeline of B7-H3–directed therapies—including antibody–drug conjugates, bispecific antibodies, and cell-based approaches—highlights growing confidence in its potential. As clinical data mature and mechanistic understanding deepens, B7-H3 is poised to play a significant role in next-generation immunotherapy strategies for solid tumors.